Sandoz Group AG ADR (D8Y0)
Market Closed
2 Jun, 09:51
XSTU 
€
68. 00
-2
-2.86%
€
- Market Cap
- P/E Ratio
0.87% Div Yield
12 Volume
- Eps
€ 70
Previous Close Want to track D8Y0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
D8Y0 closed yesterday lower at €68, a decrease of -2.86% from Monday's close, completing a monthly decrease of -3.55% or -€2.5. Over the past 12 months, D8Y0 stock gained 10.57%.
D8Y0 is not paying dividends to its shareholders.
The last earnings report, released on Mar 03, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on OTCQX (USD).
D8Y0 Chart
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Buy: Here's What You Should Know
Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks | 2 weeks ago
Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown
Switzerland's Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Wsj | 3 weeks ago
Sandoz Group AG (SDZNY) Q1 2026 Sales/Trading Call Transcript
Sandoz Group AG (SDZNY) Q1 2026 Sales/Trading Call Transcript
Seekingalpha | 1 month ago
Sandoz Group AG ADR (D8Y0) FAQ
What is the stock price today?
The current price is €68.00.
On which exchange is it traded?
Sandoz Group AG ADR is listed on XSTU.
What is its stock symbol?
The ticker symbol is D8Y0.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.87%.
What is its market cap?
As of today, no market cap data is available.
Has Sandoz Group AG ADR ever had a stock split?
No, there has never been a stock split.
Sandoz Group AG ADR Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Richard Saynor CEO | XSTU Exchange | US7999261008 ISIN |
| CH Country | 22,049 Employees | 14 Apr 2026 Last Dividend | - Last Split | - IPO Date |
Overview
Sandoz Group AG is a global leader in the development, manufacture, and marketing of generic pharmaceuticals and biosimilars. Established in 1886, the company has its headquarters in Basel, Switzerland. Sandoz operates globally, offering a wide range of therapeutic solutions aimed at improving patient outcomes. Its mission revolves around making high-quality medicines accessible to people worldwide, leveraging its extensive experience and innovation in the pharmaceutical sector.
Products and Services
- Cardiovascular - Sandoz offers a comprehensive range of products for treating cardiovascular diseases, aiming to improve heart health and patient quality of life.
- Central Nervous System - The company provides generic treatments for central nervous system disorders, focusing on medications that help manage conditions such as epilepsy and multiple sclerosis.
- Oncology - Sandoz supports cancer treatment with generic drugs and biosimilars, designed to be more accessible options for patients undergoing oncologic therapies.
- Infectious Diseases - They have a broad portfolio of antibiotics and antiviral medicines to treat various infectious diseases, contributing to global efforts in combating antimicrobial resistance.
- Pain and Respiratory - The company develops medications for managing pain and respiratory conditions, helping individuals lead more comfortable lives.
- Diabetes - Sandoz provides treatments for diabetes, focusing on improving the lives of those living with this chronic condition through more affordable therapeutic options.
- Immunology, Endocrinology, Hematology - Products in these categories include treatments for autoimmune diseases, hormonal disorders, and blood conditions, addressing a range of complex health issues.
- Ophthalmology - Sandoz also offers treatments for eye diseases, supporting vision health and preventing blindness.
- Bone Disease - The company has treatments for bone diseases, focusing on medications that help improve bone density and reduce fracture risk.
- Active Pharmaceutical Ingredients and Finished Dosage Forms - Sandoz supplies a wide range of active ingredients and finished pharmaceutical products, catering to both the manufacturing needs of the industry and the direct treatment needs of patients.
Contact Information
Address: Suurstoffi 14
Phone: 41 61 324 11 11
Website: https://www.sandoz.com
